ABPI respond to the new Northern Ireland Brexit deal

The Prime Minister confirmed today that the new Windsor Framework would ensure medicines approved for use by the UK regulator will automatically become available in Northern Ireland.

Richard Torbett, Chief Executive at the ABPI said: “While we wait to see all the details, today’s agreement appears to bring a return to a single UK market for medicines, providing the permanent solution that our members have been calling for.

“Pharmaceutical companies will now need the right amount of time to make all necessary changes. We will need to carefully consider the transition period for making these changes and ensure any new guidance is clear and provided as soon as possible.

“Alongside the measures specific to medicine regulation, it’s great news that the work on the UK’s association to Horizon Europe can begin, which will help to deliver the UK’s ambition to be a science superpower.”

  • Northern Ireland
  • Devolved Nations - Northern Ireland
  • Brexit
  • Supply

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.